The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a review (Q33788619)

29 July 2017

1 reference

title

The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a review (English)

1 reference

29 July 2017

1 reference

1 reference

Martin MV

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 October 1999

1 reference

Journal of Antimicrobial Chemotherapy

29 July 2017

published in

1 reference

29 July 2017

volume

44

1 reference

29 July 2017

issue

4

1 reference

29 July 2017

page(s)

429-437

1 reference

Candida albicans: a review of its history, taxonomy, epidemiology, virulence attributes, and methods of strain differentiation

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Molecular epidemiology of recurrent oral candidiasis in human immunodeficiency virus-positive patients: evidence for two patterns of recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Options for the management of mucosal candidiasis in patients with AIDS and HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Clinical pharmacokinetics of fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Pharmacokinetics of fluconazole after oral administration in children with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

The pharmacokinetics of oral itraconazole in AIDS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

A comparative study of the efficacy of fluconazole and amphotericin B in the treatment of oropharyngeal candidosis in patients undergoing radiotherapy for head and neck tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Candida prosthetic valve endocarditis: prospective study of six cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Fluconazole in the treatment of candidiasis in immunocompromised children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Efficacy and safety of fluconazole in the treatment of systemic fungal infections in pediatric patients. Multicentre Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

The treatment of systemic candidiasis in neonates with oral fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Resistance of Candida species to fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Fluconazole-resistant Candida species in the oral flora of fluconazole-exposed HIV-positive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Antifungal susceptibility testing: technical advances and potential clinical applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

High-dose therapy with fluconazole > or = 800 mg day-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Safety evaluation of chronic fluconazole therapy. Fluconazole Pan-American Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. The California Collaborative Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

Fatal acute hepatic necrosis due to dose-dependent fluconazole hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

High-dose itraconazole in the treatment of severe mycoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.4.429

21 January 2018

Identifiers

DOI

10.1093/JAC/44.4.429

1 reference

29 July 2017

1 reference